• Merkel cell carcinoma (MCC) is a rare and aggressive skin cancer that is more prevalent in the elderly and immunocompromised 1
-Distant metastasis beyond regional lymph nodes was the most commonly observed recurrence event • Response rates to first-line (1L) chemotherapy for metastatic MCC range from 54%-61%, as reported in retrospective studies [11] [12] [13] [14] [15] -Responses are seldom durable and survival outcomes are poor -Median duration of response (DOR) with chemotherapy iss 3-10 months, 11, 12, 14, 15 and progression-free survival (PFS) and overall survival (OS) are also typically measured in months 7, [10] [11] [12] [13] [14] [15] [16] [17] [18] • Published data on outcomes with second-line (2L) chemotherapy for distant metastatic MCC are limited to a single cohort 15 -The objective response rate (ORR) was 23%, median DOR was 3.3 months, and median PFS was 2 months in this study population (n=30) 15 • Here we present a study of real-world/observational outcomes with 2L or later chemotherapy in patients with distant metastatic MCC in the United States
STUDY OBJECTIVES
• Primary objective: -Assess ORR based on best overall response (BOR) to 2L or later chemotherapy using Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1) as a guide 19 • Key secondary objective: -Assess DOR, PFS, OS, time to treatment discontinuation (TTD), and durable response rate (DRR) in patients receiving 2L or later chemotherapy
METHODS

Patient eligibility criteria
• Inclusion criteria -Adult patients (≥18 years) diagnosed with distant metastatic MCC -≥2 lines of systemic chemotherapy for distant metastatic MCC, including a platinum-based agent (cisplatin or carboplatin) ± etoposide, cyclophosphamide + doxorubicin + vincristine, epirubicin, topotecan, irinotecan, gemcitabine, nab-paclitaxel, or docetaxel -Availability of prior MCC medical history and evidence of continuity of care or documented record of death, including ≥1 visit following the initiation of 2L or later systemic chemotherapy • Exclusion criteria -History of any solid tumour, with the exception of basal or squamous cell carcinoma of the skin, bladder carcinoma in situ, or cervical carcinoma in situ, in the 3 years prior to start of 2L or later chemotherapy -Prior treatment with any antibody/drug targeting T-cell co-regulatory proteins or enrolment in any interventional clinical trial
Study populations
• The primary analysis group was immunocompetent patients with distant metastatic MCC who had received ≥2 lines of chemotherapy within the study period of 01 November 2004 to 30 September 2014 • Data were also analysed in the overall study population of both immunocompetent and immunocompromised patients diagnosed with distant metastatic MCC who had received ≥2 lines of chemotherapy -Immunocompromised patients were defined as follows:
• CD4 count <500 at any time in the 12 months prior to study period or diagnosis of HIV • Diagnosis of select haematologic diseases (chronic lymphocytic leukaemia, multiple myeloma, or hypogammaglobulinaemia) in the 5 years prior to study entry • Documented organ or allogeneic stem cell transplant prior to study entry or during the follow-up period • Select immunosuppressive treatment during the 28 days prior to date of 2L or later chemotherapy initiation or during the follow-up period
Data collection and analysis
• Data were obtained from iKnowMed™ (iKM), an oncology-specific electronic health record system maintained by McKesson Specialty Health that captures outpatient encounter histories from US Oncology Network (USON) practices -Death information was obtained from the Social Security Death Index (SSDI) and supplemented with deaths recorded in iKM -Data were handled in compliance with the Health Insurance Portability and Accountability Act and the Health Information Technology for Economic and Clinical Health Act • BOR was assessed through clinical review of electronic health records (EHRs), using RECIST v1.1 as a guide • Kaplan-Meier methodology was used to assess time to event outcomes • DRR was defined as the proportion of patients with a complete response or partial response lasting ≥6 months • Safety was not assessed in this study
RESULTS
• Patient selection is shown in Figure 2 , and characteristics of the immunocompetent and overall study populations are shown in Patients not treated with chemotherapy (n=62)
Patients not treated with qualifying regimens (n=12)
Patients without 1L and 2L chemotherapy treatment (n=97)
Patients assessed for eligibility (n=255)
Eligible patients available for analysis (n=20)
Patients not meeting eligibility criteria based on review of individual EHR (n=19) • ORR was 28.6% in the immunocompetent population and 20.0% in the overall population ( Table 2) -There were no responses in patients classified as immunocompromised • The 6-month DRR was 0% in both populations -No patients were censored, as all patients had disease progression or died during the study Table 2 . Best overall response to 2L or later chemotherapy • Median PFS in the immunocompetent and overall populations was 2.2 months (95% CI, 1.2-3.5) and 2.1 months (95% CI, 1.0-3.2), respectively ( Figure 3A and 3B) • PFS rate at 6 months for both patient populations was 0% 
DISCUSSION
• In a recent retrospective analysis of 30 patients with distant metastatic MCC treated with chemotherapy in the 2L setting in the United States, the ORR was 23.0%, median DOR was 3.3 months, and median PFS was 2.0 months 15 • In a retrospective analysis of patients with distant metastatic MCC treated with 2L or later chemotherapy in the European Union, the ORR was 8.8% in the overall population of 34 patients and 10.3% in 29 immunocompetent patients 20 -Median PFS was 3.0 months in both populations -Lower response rates were likely due to the lower frequency of patient screening in Europe per clinical practice 16, 17 compared with the US studies • Median DOR, median PFS (Figure 5) , and median OS were comparable across these 3 retrospective observational studies, confirming the lack of response durability with chemotherapy 
